Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apogee Therapeutics, Inc. - Common Stock (NQ: APGE ) 48.03 +1.99 (+4.32%) Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 315,789 Open 46.32 Bid (Size) 19.20 (2) Ask (Size) 50.96 (1) Prev. Close 46.04 Today's Range 45.61 - 49.45 52wk Range 14.19 - 72.29 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Apogee Therapeutics to Participate in Upcoming June Investor Conferences May 23, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases May 15, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Performance YTD +68.47% +68.47% 1 Month +3.20% +3.20% 3 Month +37.58% +37.58% 6 Month +179.24% +179.24% 1 Year +126.24% +126.24% More News Read More APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 May 13, 2024 Via InvestorPlace Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results May 13, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Earnings Superstars: 3 Stocks Primed to Outperform This Quarter May 08, 2024 Via InvestorPlace Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference May 06, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases March 25, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Top 3 Health Care Stocks That Are Ticking Portfolio Bombs March 14, 2024 Via Benzinga Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million March 12, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering March 07, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 March 05, 2024 Via InvestorPlace Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Crude Oil Down 1%; Dave Shares Jump After Q4 Results March 05, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Tuesday's Intraday Session March 05, 2024 Via Benzinga Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 05, 2024 Via Benzinga Nasdaq Down 250 Points; ISM Services PMI Falls In February March 05, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday? March 05, 2024 Via Benzinga NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday March 05, 2024 Via Benzinga Topics Stocks Exposures US Equities Dow Dips Over 100 Points; Target Posts Upbeat Earnings March 05, 2024 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 05, 2024 Via Benzinga IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome March 05, 2024 Via Investor's Business Daily Topics Initial Public Offering Exposures Securities Market Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of March 05, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 March 04, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire IPO watch 2024: Which new stocks will hit the market? January 08, 2024 Via MarketBeat Topics Initial Public Offering Exposures Securities Market Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.